1379577-36-2

Upstream product

• 1379575-57-1 t-butyl 2-(2-methyl-1-p-tolylpropan-2-yl)hydrazinecarboxylate 
• 139399-09-0 ethyl 3-(dimethylamino)-2-(4-hexylphenyl)acrylate 
• 14377-22-1 2-(4-hexylphenyl)acetic acid 
• 14377-28-7 ethyl 2-(4-hexylphenyl)acetate 
• 67510-95-6 2-methyl-1-(p-tolyl)propan-2-amine 
• 1267527-84-3 2-chloro-N-(2-methyl-1-(p-tolyl)propan-2-yl)acetamide 
• 20834-59-7 2-methyl-1-(4-methylphenyl)propan-2-ol 

Relevant academic research and scientific papers

Method for producing hematopoietic stem cells using pyrazole compounds

An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).

PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA

Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or —(CR6, R7)n—, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.